Work

Lebrikizumab Provides Progressive Improvements in Skin Clearance and Itch Relief Over One Year in Patients with Atopic Dermatitis

Year: 2023

Type: article

Abstract: Scan or click the QR code for a list of all Lilly content presented at the congress.Other company and product names are trademarks of their respective owners.This study was funded by Dermira, a wholly owned subsidiary of Eli Lilly and Company.Almirall, S.A. has licensed the rights to develop and commercialize lebrikizumab for the treatment of dermatology indications, including atopic dermatitis, in Europe.

Source: SKIN The Journal of Cutaneous Medicine

DOI: 10.25251/skin.7.supp.278

Authors: April Armstrong, Kamran Ghoreschi, David Rosmarin, Todd Schlesinger, Alan Irvine, Anthony Bewley, Marta Casillas, Gaia Gallo, Yuxin Ding, Chenjia Xu, Ignasi Pau-Charles, Eric Simpson

Institutions: University of California, Los Angeles, Humboldt-Universität zu Berlin, Freie Universität Berlin, Charité - Universitätsmedizin Berlin, Indiana University School of Medicine, Children's Health Ireland at Crumlin, Royal London Hospital, Eli Lilly (United States), Almirall (Spain), Oregon Health & Science University

Language: English

Topic: Dermatology and Skin Diseases

Subfield: Dermatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

Funders: Eli Lilly and Company, Pfizer, Sanofi, Regeneron Pharmaceuticals, Dermira, Galderma, LEO Pharma, Sanofi Genzyme

OpenAlex ID: W4388625653

FWCI:

Cites: 1

Cited by:

Related to: 10